Clinical trial NCT06109948: Study to Assess the Safety, Tolerability, PK and PD of ABX1100
Official title: A Phase 1a/1b, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Healthy
Late Onset Pompe Disease
Lead sponsor: Aro Biotherapeutics
Sponsor class: INDUSTRY
First posted: 2023-10-31
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study ABX1100-1001 is a first-in-human (FIH), phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) and multiple doses (MD) of ABX1100 administered intravenously to healthy participants and patients with LOPD.

* Part A features a SAD study with a double-blind, placebo-controlled, randomized design in NHVs involving 3 cohorts (A1-A3). This Part also includes a single dose, open-labeled cohort (A4) in NHVs which will commence after cohorts A1-3.
* Part B is a MD, double-blind, placebo-controlled, randomized design in NHVs. The MD Part B will commence after completion of Cohorts A1, A2 and A3 in the SAD Part A and SRC review of these 3 cohorts.
* Part C opened for enrollment after the Safety Review Committee (SRC) review of safety, PK and PD data from both Part A and Part B. Part C is a MD, open-label design in patients with Late-Onset Pompe Disease.


Eligibility criteria: Parts A-B Inclusion Criteria:

* Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive and weight between 50 and 90 kg, inclusive.
* Agree not to have a tattoo or body piercing until the end of the study.
* Agree not to receive COVID-19 vaccination from 7 days prior to first study drug administration until at least 7 days after the last study drug administration.
* Agree not to receive a vaccination (live attenuated vaccine) during the study and until 60 days after the study has ended (last study procedure).
* Willing to undergo needle muscle biopsies.
* Willing to avoid strenuous activities 48 hours before needle muscle biopsy and throughout the study.
* Female participants who are sexually active with a non-sterilized partner must be non-pregnant and non-lactating and agree to use a highly effective method of contraception.
* Males of childbearing potential must agree to use a highly effective method of contraception with female sexual partners of childbearing potential and not donate sperm during study participation and for 90 days after last administration of study drug ABX1100 or placebo.

Parts A-B Exclusion Criteria:

* Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition.
* History of any inherited or acquired skeletal muscle diseases (for example, Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy, Spinal Muscular Atrophy (SMA), Polymyositis, Rhabdomyolysis and Inclusion Body Myositis (IBM).
* History of any inherited or acquired cardiac disease including congestive heart failure, ischemic heart disease, or arrhythmias; an abnormal ECG.
* History of cancer within past 5 years, with the exception of treated or excised skin basal cell carcinoma.
* Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks prior to the screening visit
* Presence of any significant physical or organ abnormality.
* Major surgery within 6 months prior to the start of the study.
* Current smoker, recent history of smoking and/or use of any nicotine-containing products (within past 6 months).
* A known history or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody or human immunodeficiency virus (HIV) infection.
* Currently participating in another investigational trial or have received any investigational drug within the past 30 days.

Part C Key Inclusion criteria

* Male or female LOPD patients aged ≥ 18 years (inclusive) of age, at the time of informed consent.
* Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive and weight \>50 kg.
* Agree not to receive COVID-19 vaccination from 7 days prior to first study drug administration until at least 7 days after the last study drug administration or after the final study procedure, whichever is later.
* Agree not to receive a vaccination (live attenuated vaccine) during the study and until 60 days after the study has ended (last study procedure).
* Willing to undergo needle muscle biopsies.
* Documented Acid alpha-glucosidase (GAA) deficiency and mutation analysis from blood, skin, or muscle tissue for confirmation of diagnosis of LOPD.
* Currently receiving a stable dose of standard of care enzyme replacement therapy (ERT) regularly for a minimum of 6 months immediately prior to study entry
* Capable of walking 50 meters with or without an assistive device.
* Predicted upright Forced Vital Capacity (FVC) \>= 30% within the past year prior to study entry, not requiring invasive mechanical ventilation. Non-invasive, temporary, respiratory support is acceptable
* Female participants who are sexually active with a non-sterilized partner must be non-pregnant and non-lactating and agree to use a highly effective method of contraception.
* Males of childbearing potential must agree to use a highly effective method of contraception with female sexual partners of childbearing potential and not donate sperm during study participation and for 90 days after last administration of study drug ABX1100.

Part C Key Exclusion criteria

* History of muscle biopsy within 1 month of Day 1 or planning to undergo non-study related muscle biopsies during study period.
* History of coronary artery disease or cardiovascular disease.
* History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
* Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
* Resting seated blood pressure \< 90/40 mmHg or \> 140/90 mmHg , unless deemed not clinically significant by the PI/Sub-Investigator.
* Resting seated heart rate \< 45 bpm or \> 99 bpm, unless deemed not clinically significant by the PI/Sub-Investigator.
* Intolerance to and/or difficulty with blood sampling through venipuncture.
* Positive pregnancy test for female participants.
* Currently participating in another investigational trial or have received any investigational drug within the past 30 days or 5 elimination half-lives of the investigational drug, whichever is longer, prior to dosing.
* Requires a wheelchair or invasive ventilation.
* Fridericia's corrected QT (QTcF) \> 450 ms for participants or history of QT interval prolongation unless deemed not clinically significant by the PI/Sub-Investigator.
* Uncontrolled diabetes (Hemoglobin A1c \[HbA1c\] equal to or higher than 7.5%).
* A known history or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody or human immunodeficiency virus (HIV) infection.

Primary outcomes:
measure: Number of subjects with treatment-emergent adverse events (TEAEs)
timeFrame: up to 20 weeks
Secondary outcomes:
measure: Plasma pharmacokinetics as measured by Cmax
timeFrame: 0-8 hours after ABX1100 administration
measure: Plasma pharmacokinetics as measured by Tmax
timeFrame: 0-8 hours after ABX1100 administration
measure: Plasma pharmacokinetics as measured by AUC
timeFrame: 0-8 hours after ABX1100 administration
measure: Immunogenicity of AXB1100 as measured by anti-ABX1100 antibodies in serum
timeFrame: Up to 16 weeks
Other outcomes:
Locations:
city: Fairfax
country: United States
facility: Lysosomal and Rare Disorders Research and Treatment Center, Inc
state: Virginia
city: Calgary
country: Canada
facility: MAGIC clinic
state: Alberta
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
Study officials:
References: